Dr Reddy’s yen for growth: Indian generics and API firm plans to partner in Japan

By Gareth Macdonald

- Last updated on GMT

Abhijit Mukherjee, Dr. Reddy’s COO eyeing Japanese generics marlket
Abhijit Mukherjee, Dr. Reddy’s COO eyeing Japanese generics marlket

Related tags Dr. reddy Japan

Dr Reddy’s has set out to build in the Japanese market days after revealing that higher generic and API sales elsewhere had been pegged back by currency fluctuations.

Abhijit Mukherjee, Dr. Reddy’s COO, outlined its plan this week, telling in –Pharmatechnologist.com ongoing Government efforts​ to increase the number of non-branded medicines used in the country would make it an important market.

The Japanese generics segment is slated to grow at 8– 10% between 2015- 2019 with generic penetration targeted to touch 60% in the next few years” the firm said, adding that  “the Japanese market is an important growth driver for Dr. Reddy’s​.“

Dr. Reddy's intends to create a value accretive, highly profitable business in Japan through a portfolio of complex generics, biosimilar and specialty products, which will be brought to market in collaboration with Japanese partners​.”

The approach matches the strategy by a group representing Indian drugmakers and ingredients suppliers at a tradeshow in Tokyo last month​.

Yen for stability

Generating more revenue in Japan could also help Dr. Reddy’s lessen the negative impact currency fluctuations elsewhere have had on its business as  the value of the Japanese yen has been relatively stable so far in 2015​.

This contrasts with Russia’s rouble and Venezuela’s bolivar, fluctuations in the value of which saw Dr. Reddy’s fall short​ of analysts’ fourth quarter profit estimates for the financial year 2015.

According to a report published by the firm last week, net profit for the fiscal fourth quarter ended March 31 was INR5.18bn ($81.4m) up 7.7% on the year earlier period but short of the INR5.9bn expected by analysts survey by Bloomberg​.

Currency fluctuations aside, Dr. Reddy’s is confident its generic and API business will grow in fiscal 2016.

Mukherjee told us “business growth was primarily driven by generic launches of our oncology APIs in mature markets and our portfolio of complex APIs in emerging markets” ​citing South East Asia, the Middle East, Mexico, Latin America as important.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more